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Abstract
Bluetongue virus (BTV) is the causative agent of a major disease of livestock (bluetongue). For over two decades, it has been
widely accepted that the 10 segments of the dsRNA genome of BTV encode for 7 structural and 3 non-structural proteins.
The non-structural proteins (NS1, NS2, NS3/NS3a) play different key roles during the viral replication cycle. In this study we
show that BTV expresses a fourth non-structural protein (that we designated NS4) encoded by an open reading frame in
segment 9 overlapping the open reading frame encoding VP6. NS4 is 77–79 amino acid residues in length and highly
conserved among several BTV serotypes/strains. NS4 was expressed early post-infection and localized in the nucleoli of BTV
infected cells. By reverse genetics, we showed that NS4 is dispensable for BTV replication in vitro, both in mammalian and
insect cells, and does not affect viral virulence in murine models of bluetongue infection. Interestingly, NS4 conferred a
replication advantage to BTV-8, but not to BTV-1, in cells in an interferon (IFN)-induced antiviral state. However, the BTV-1
NS4 conferred a replication advantage both to a BTV-8 reassortant containing the entire segment 9 of BTV-1 and to a BTV-8
mutant with the NS4 identical to the homologous BTV-1 protein. Collectively, this study suggests that NS4 plays an
important role in virus-host interaction and is one of the mechanisms played, at least by BTV-8, to counteract the antiviral
response of the host. In addition, the distinct nucleolar localization of NS4, being expressed by a virus that replicates
exclusively in the cytoplasm, offers new avenues to investigate the multiple roles played by the nucleolus in the biology of
the cell.
Citation: Ratinier M, Caporale M, Golder M, Franzoni G, Allan K, et al. (2011) Identification and Characterization of a Novel Non-Structural Protein of Bluetongue
Virus. PLoS Pathog 7(12): e1002477. doi:10.1371/journal.ppat.1002477
Editor: Mark Heise, University of North Carolina at Chapel Hill, United States of America
Received July 1, 2011; Accepted November 26, 2011; Published December 29, 2011
Copyright:  2011 Ratinier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by the Wellcome Trust, the Scottish Funding Council and the Italian Ministry of Health. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: massimo.palmarini@glasgow.ac.uk
Introduction
Bluetongue is a major infectious disease of ruminants caused by
an arbovirus (Bluetongue virus, BTV) transmitted by biting midges
(Culicoides spp.) [1–3]. Historically, bluetongue has been endemic
almost exclusively in temperate and tropical areas of the world
where the climatic conditions favour both the spread of the
susceptible insect vector population and the virus replication cycle
within the vector [4]. However, in the last decade BTV has spread
extensively in several geographical areas including Southern
Europe and also, unexpectedly, in Northern Europe causing a
serious burden to both animal health and the economy [5,6].
From a molecular and structural virology perspective BTV is
one of the best understood animal viruses. BTV is a member of the
Orbivirus genus, within the Reoviridae family, and possesses a double-
stranded RNA genome formed by 10 segments (Seg-1 to Seg-10)
of approximately 19200 base pairs in total [1,3]. Until now, the
BTV genome has been shown to encode for 7 structural and 3
non-structural proteins. The BTV genome is packaged within a
triple layered icosahedral protein capsid of approximately 90 nm
in diameter [1,7–10]. The outer capsid of the virion is composed
by 60 trimers of VP2 and 120 trimers of VP5 [11] and differences
within this outer capsid define the 26 BTV serotypes which have
been described so far [12,13]. The outer capsid proteins, and VP2
in particular, stimulate virus neutralizing antibodies which in
general protect only against the homologous serotype [14]. The
internal core is formed by two layers, constituted by VP3 (sub-
core) and the immunodominant VP7 (intermediate layer) [7].
Three minor enzymatic proteins, VP1 (RNA dependent RNA
polymerase), VP4 (capping enzyme and transmethylase) and VP6
(RNA dependent ATPase and helicase) are contained within the
core that is transcriptionally active in infected cells [15–21].
The BTV genome encodes also 3 non-structural proteins: NS1,
NS2 and NS3/NS3a. NS1 and NS2 are highly expressed viral
proteins and their multimers are morphological features of BTV-
infected cells. Multimers of the NS1 protein form tubules
(approximately 50 nm in diameter and up to 1000 nm in length)
that appear to be linked to cellular cytopathogenicity [22], while
NS2 is the major component of the viral inclusion bodies. NS2
plays a key role in viral replication and assembly as it has a high
affinity for single stranded RNA and possesses phosphohydrolase
activity [23]. NS3/NS3a are glycosylated proteins involved in
BTV exit. There are two isoforms of NS3: NS3 and NS3a with the
latter lacking the N-terminal 13 amino acid residues [24–26].
Therefore, the segmented genome of BTV has been thought to
be monocistronic (i.e. ten genome segments encoding for 10
proteins) for almost three decades [27,28]. Segment 9 however,
contains the open reading frame (ORF) encoding VP6 but also a
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present in BTV and some related Orbiviruses such as African horse
sickness virus and others [29]. Bioinformatic analysis predicts that
the BTV ‘‘ORFX’’ encodes for a protein of 77–79 amino acid
residues. This putative ORFX is subject to functional constraints
at the amino acid level and its level of conservation is higher
compared to that of the overlapping VP6. In addition, the ORFX
putative AUG initiation codon has a strong Kozak context
suggesting that this protein might be translated by leaky scanning
[29]. Alternative reading frames are expressed in a variety of RNA
viruses and they can play fundamental roles in viral replication
and virus-host interaction. In this study, we identified a previously
unknown non-structural protein and characterized its biological
properties.
Materials and Methods
Ethics statement
All experimental procedures carried out in this study are
included in protocol number 5182/2011 of the Istituto G.
Caporale approved by the Italian Ministry of Health (Ministero
della Salute) in accordance with Council Directive 86/609/EEC
of the European Union and the Italian D.Igs 116/92.
Cell cultures
BSR cells (a clone of BHK21, kindly provided by Karl K.
Conzelmann) were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS).
Bovine foetal aorta endothelium (BFAE) cells were obtained from
the Health Protection Agency (HPA) cell culture collection
(catalogue number 87022601), and were grown in Ham’s F12
medium supplemented with 20% FBS. CPT-Tert cells [30] are
sheep choroid plexus cells immortalized with the simian virus 40
(SV40) T antigen and human telomerase reverse transcriptase
(hTERT) and were kindly provided by David Griffiths. CPT-Tert
cells were grown in Iscove’s modified Dulbecco’s medium
(IMDM), supplemented with 10% FBS. Mammalian cell lines
were cultured at 35 to 37uC, in a 5% CO2 humidified atmosphere.
C6/36 cells are mosquitoes cells established from Aedes albopictus
and were kindly provided by Richard Elliott. C6/36 cells were
grown in Leibovitz’s L-15 medium supplemented with 10% FBS
and 10% tryptose phosphate broth. KC cells [31](established from
Culicoides sonorensis larvae) were grown in Schneider’s insect
medium and were supplemented with 10% FBS. Insect cells were
incubated at 28uC.
Plasmids and antisera
Initially, the open reading frame expressing ORFX (NS4) was
amplified by PCR from BTV-10 (GenBank accession number
D00509) and cloned into the pCI Mammalian Expression Vector
(Promega) resulting into pCI-NS4. The BTV-8 NS4 was cloned
into the peGFP-N1 vector (Clontech), resulting in plasmid pNS4-
GFP. pNS47–77-GFP, pNS413–77-GFP and pNS419–77-GFP are
mutants derived from pNS4-GFP expressing NS4 truncated of the
amino terminal 6, 12 and 18 amino acid residues, respectively.
pNS47–77-GFP, pNS413–77-GFP and pNS419–77-GFP maintain the
methionine and valine residues in position 1 and 2 of NS4. Note
that BTV-10 and BTV-1 NS4 are 100% identical at the amino
acid level. While BTV-8 and BTV-1 NS4 differ for a single amino
acid residue in position 6. The set of BTV-1 and BTV-8 plasmids
necessary to rescue these viruses in vitro by reverse genetics were
obtained following the method recently published by Boyce and
colleagues [26]. Briefly, total RNA was extracted from infected
cells using Trizol (Invitrogen) according to the manufacturer’s
instructions. Each BTV genome segment was amplified by RT-
PCR using the AccuScript PfuUltra II RT-PCR Kit (Agilent) from
either BTV-1 or BTV-8 dsRNA preparations and the resulting
PCR products were gel-purified (Qiagen) and cloned into either
pUC57 (Fermentas) or pCI. Each BTV segment was cloned
downstream of a T7 promoter and upstream of a BsaI or SapI
restriction site. All of the mutants described in this study were
obtained using the QuikChange II Site-Directed Mutagenesis Kit
(Stratagene), according to the manufacturer’s instructions. All
plasmids used in this study were completely sequenced before use.
Sequences of PCR primers used in this study are available upon
request. Antisera used in this study included polyclonal rabbit
antisera raised against BTV VP7, NS1, NS2, NS3 and ORFX
(NS4) expressed in bacteria as Glutathione S-transferase (GST)-
tagged recombinant proteins (Proteintech Group, Inc.). Antiserum
against BTV-1 NS4 was raised against a recombinant GST fusion
protein including the entire NS4 protein expressed in bacteria.
Polyclonal rabbit antiserum against BTV VP6 was kindly provided
by Polly Roy as previously described [32]. Antibodies against B23
and c-tubulin were obtained commercially (Sigma Aldrich).
Viruses
BTV-8 (IAH reference collection number NET2006/04) was
originally isolated from a naturally infected sheep during the 2006
outbreak in Northern Europe [33]. The virus was passaged once in
KC cells and once in BHK21 cells. The reference strain of BTV-1
was originally isolated at the ARC – Onderstepoort Veterinary
Institute (IAH reference collection number RSArrrr/01) and was
adapted to cell culture by passaging it twice in embryonated eggs
and 9 times in BHK21 cells. Both viruses were kindly provided by
Peter Mertens. Virus stocks were prepared by infecting BSR cells
at a multiplicity of infection (MOI) of 0.01 and collecting the
supernatant when obvious cytpopathic effect (CPE) was observed.
The supernatants were clarified by centrifugation at 500 g for
5 min and the resulting virus suspensions aliquoted and stored at
4uC for short term usage and at 270uC for long term storage.
Virus titres were determined by standard plaque assays using BSR
or CPT-Tert cells [34].
Author Summary
Bluetongue is a major infectious disease of ruminants
caused by bluetongue virus (BTV), an ‘‘arbovirus’’ trans-
mitted from infected to susceptible hosts by biting
midges. Historically, bluetongue has been endemic almost
exclusively in temperate and tropical areas of the world.
However, in the last decade BTV has spread extensively in
several geographical areas causing a serious burden to
both animal health and the economy. BTV possesses a
double-stranded RNA segmented genome. For over two
decades, it has been widely accepted that the 10 segments
of BTV genome encode for 7 structural and 3 non-
structural proteins. In this study we discovered that BTV
expresses a previously uncharacterized non-structural
protein that we designated NS4. Although BTV replicates
exclusively in the cytoplasm, we found NS4 to localize in
the nucleoli of the infected cells. Our study shows that NS4
is not needed for viral replication both in mammalian and
insect cells, and in mice. However, NS4 confers a
replication advantage to BTV in cells in an antiviral state
induced by interferon. In conclusion, we have elucidated a
possible route by which BTV can counteract the defences
of the host.
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65 full-length segment 9 sequences representing 24 BTV
serotypes were obtained from GenBank. Amino acid conservation
plots and secondary structure predictions were obtained using the
CLC Genomics Workbench(CLC, Aarhus, Denmark) software and
bioinformatics tools available online (the PSIPRED server [http://
bioinf.cs.ucl.ac.uk/psipred], and the Network Protein Sequence
Analysis (nps@) server, [http://npsa-pbil.ibcp.fr/]).
Reverse genetics
Recombinant BTVs were rescued by reverse genetics as
previously described [26]. Briefly, plasmids containing the genomic
segments of BTV-1 or BTV-8 or resulting mutants were linearized
with the appropriate restriction enzymes and then purified by
phenol-chloroform extraction. Digested plasmids were used as a
template for in vitro transcription using the mMESSAGE mMA-
CHINE T7 Ultra Kit (Ambion), according to the manufacturer’s
instructions. ssRNAs were purified sequentially by phenol/chloro-
form extraction and through Illustra Microspin G25 columns (GE
Healthcare Life Sciences), following the manufacturer’s protocol.
Monolayers of 95% confluent BSR cells grown in 12 well plates
were transfected twice with BTV RNAs using Lipofectamine 2000
(Invitrogen). Firstly, 0.5610
11 (BTV-1) or 1610
11 (BTV-8)
molecules of each of the BTV segments encoding VP1, VP3,
VP4, NS1, VP6 and NS2 were diluted in Opti-MEM I Reduced
Serum Medium containing 0.5 U/mL of RNAsin plus (Promega)
and then mixed with Lipofectamine 2000 diluted in Opti-MEM I
Reduced Serum Medium. After 25 min of incubation at room
temperature, the mixture was added to the cells. 16 to 18 h after the
first transfection, the cells were transfected as before but with all 10
BTV segments. 3 to 4 h after the second transfection the cells were
overlaid with 2 ml of minimal essential media containing 1.5%
agarose type VII and 2% FBS, and monitored for development of
plaques. Finally, individual BTV rescued clones were picked
through the agarose overlay and used to infect fresh BSR cells in
order to obtain a virus stock. Where necessary, BTV dsRNA was
extracted from infected cells using Trizol (Invitrogen). The ssRNA
fraction was precipitated using lithium chloride, and the harvested
dsRNA fraction was precipitated using isopropanol in the presence
of sodium acetate.
Virus growth curves
Growth curves of BTV recombinant viruses used in this study
were derived in cells infected at a MOI of 0.05 and testing for the
presence of infectious virus in supernatants collected at 8, 24, 48,
72 and 96 h post-infection. Virus growth was also assessed in cells
in the presence of 1000 antiviral units/ml (AVU/ml) of interferon
Tau (IFNT) or universal type I interferon (UIFN). Recombinant
ovine IFNT was kindly provided by Tom Spencer. IFNT was
produced in Pichia pastoris and purified as described previously
[35]. Universal type I Interferon (UIFN) was obtained from PBL
InterferonSource. BFAE cells and CPT-Tert cells were treated
with 1000 AVU of IFN 20 h prior infection with BTV
recombinants at a MOI of 0.1 (BFAE and CPT-Tert), 0.01 or
0.001 (CPT-Tert). Two hours after infection, the medium was
replaced and the cells maintained in the presence of either IFNT
or UIFN at the original concentration. Cell supernatants were
collected at 24, 48 and 72 h post-infection, centrifuged for 5 min
at 500 g in order to pellet cell debris and virus infectivity was
subsequently titrated by endpoint dilution analysis on BSR cells.
Viral titers were calculated by the method of Reed & Muench and
expressed as log10 TCID50/ml [36]. Each experiment was
performed two to three times, each time in duplicate, using
different stocks for each virus.
Interferon protection assay
CPT-Tert cells were plated in 24-well plates and treated for 20 h
with1000 AVU/ml of IFNT or UIFN and then infected with either
BTV-1 or BTV-8 at different MOIs (0.1, 0.01 and 0.001). The
medium was replaced 2 h after infection and the cells maintained in
the presence of either IFNT or UIFN at the original concentration.
At 72 h post-infection, the cells were washed once with phosphate
buffered saline (PBS; pH 7.4) and stained for 16 h using a 0.5%
crystal violet/10% formaldehyde solution. We used Image-Pro Plus
(MediaCybernetics),inorder to quantify in each well thepercentage
of the monolayer that was disrupted after BTV replication. Results
were expressed as the percentage of destroyed monolayer by
calculating for each well the following formula: (number of pixels
above background: total number of pixels times) X 100.
Transfections
BSR cells were transfected with 0.6–1.8 mg of either pCI-NS4,
pNS4-GFP or derived deletion mutants, using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Western blotting
For western blot analyses of intracellular proteins, cells were lysed
by standard techniques as described previously [37]. For viral pellet
analysis, cell supernatants were collected and viral particles
concentrated 200 times by ultracentrifugation as previously
described [38]. Protein expression was assessed by sodium-
dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and western blotting using the various antisera as indicated above.
Membranes were incubated with a horse radish peroxidase-
conjugated secondary antibody (GE Healthcare Life Sciences) and
developed by chemiluminescence using Amersham ECL Plus
Western Blotting Detection Reagents (GE HealthcareLife Sciences).
Confocal microscopy
Experiments were performed using BSR, BFAE, CPT-Tert or
C6/36 cells cultured in two-well glass chamber slides (Lab-Tek,
Nalge Nunc International). Cells were either transfected with
appropriate plasmids or infected with various BTV strains at a
MOI between 0.01 and 1.5. Cells were washed with PBS and fixed
with 5% formaldehyde for 15 minutes. The fixed cells were then
processed as described previously [39] and incubated with the
appropriate antisera. Secondary antibodies were conjugated with
Alexa Fluor 488 (Invitrogen, Molecular Probes) or Alexa Fluor
594 (Invitrogen, Molecular Probes). Slides were mounted using
VECTASHIELD Mounting Medium with DAPI (49,6-diamidino-
2-phenylindole, Vector Laboratories). Slides were analysed and
images collected using a Leica TCS SP2 confocal microscope.
Electron microscopy
BSR cells were infected with BTV-1, BTV-8 or the corre-
sponding deletion mutants at a MOI of 0.05 in 35 mm dishes. At
24 h post-infection, cells were fixed using cold 2.5% gluteralde-
hyde and 1% osmium tetroxide. Cells were subsequently pelleted
through 1% SeaPlaque agarose (Flowgen), dehydrated using a
graded alcohol series and embedded in Epon 812 resin, followed
by cutting and analysis in a Joel 1200 EX II electron microscope.
In vivo pathogenicity studies
Animal experiments were carried out at the ‘‘Istituto G.
Caporale’’ (Teramo, Italy) following local and national approved
protocols regulating animal experimental use.
Study 1. Litters of 3-day old NIH-Swiss mice (n=8–12), were
inoculated intra-cerebrally with 10
3 TCID50 of either BTV-1,
A Novel BTV Non-Structural Protein
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included litters inoculated with tissue culture media. Mice were
euthanized at three weeks p.i. or earlier if showing advanced
clinical signs of encephalitis. For each virus, two litters were
inoculated using two different virus preparations.
Study 2. Age-matched adult transgenic mice, deficient in the
type I interferon (IFN) receptor [IFN Alpha Ro/o IFNAR
(2/2)
129/Sv], were inoculated intraperitoneally with 100 PFU of either
BTV-1, BTV-8, BTV-1DNS4 or BTV-8DNS4. For each virus,
two groups (n=5) of mice were inoculated using two different
virus preparations. Survival plots were constructed using data
collected from two experimental groups (n=10) with the exception
of a mock infected group that was constituted by a single group of
6 mice. Formalin-fixed and paraffin-embedded brains tissue
sections from inoculated (and mock inoculated) mice were used
in immunohistochemistry. Sections (4–6 mm) were examined for
the presence of BTV NS4 using a polyclonal NS4 antiserum and
the EnVision (DAKO) detection system.
Results
BTV expresses a previously uncharacterized non-
structural protein that localizes in the cell nucleolus
The BTV genome is formed by 10 segments. Segment 9
contains an open reading frame (ORF) between nucleotides 182
and 418 (Figure 1A) in position +1 with respect to the major ORF
expressing VP6 [29]. In silico analysis showed that this extra ORF
is highly conserved and encodes a putative protein of 77–79 amino
acid residues. A stretch of 11 basic amino acid residues is present
in the N terminal portion of the protein (residues 3 to 20). In
Figure 1. BTV expresses a fourth non structural protein (NS4). (A) BTV segment 9 (1049 base pairs). The VP6 protein (dark gray) is encoded by
nucleotides 16 to 1002. The NS4 coding sequence is located in the +1 open reading frame (ORF) between nucleotides 182 to 418. VP6 (residues 57 to
135) and NS4 (residues 1 to 79) amino acid conservation plots are shown. NS4 secondary structure prediction indicated the presence of two putative
a-helices, drawn in blue and red. The N-terminal domain (blue) is highly basic and the C-terminal domain (red) contains a conserved leucine zipper
motif. (B) Western blotting of cellular extracts (lysate) of BSR cells either transfected with 1.8 mg of plasmid expressing NS4 alone (pcI-NS4) or in fusion
with eGFP (peGFP-NS4), or infected by BTV-8 or BTV-1 at a MOI of 0.01. Cells were analyzed 36 h post-transfection or infection and blots were
incubated with NS4 antiserum. (C) Western blots of viral pellets and cell protein extracts of BFAE cells infected by BTV-1 at a MOI of 0.05. Samples
were analyzed at 48 h post-infection by SDS-PAGE and western blotting employing antisera against NS1, VP6, VP7, ORFX (NS4) and c-tubulin as
indicated. (D) Immunohistochemical detection of NS4. Immunohistochemistry was performed as described in Materials and Methods in brain tissue
sections of mice inoculated with BTV-8 72 h post-infection using an antiserum against NS4. Cells expressing NS4 are stained brown as indicated by
white arrows. No expression of NS4 is detected in negative control mice mock-inoculated with cell culture media.
doi:10.1371/journal.ppat.1002477.g001
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PLoS Pathogens | www.plospathogens.org 4 December 2011 | Volume 7 | Issue 12 | e1002477Figure 2. NS4 localises in the nucleoli of transfected and infected cells. (A) Confocal microscopy of CPT-Tert cells transfected with pCI-NS4
or empty pCI as a control. At 24 h post-transfection, cells were fixed and analyzed by immunofluorescence using antibodies against NS4 and as
indicated the nucleolar marker B23 with the appropriate conjugated secondary antibodies as described in the Materials and Methods. Scale bars
correspond to 18 mm. (B) Confocal microscopy of BSR cells infected by BTV-1 and BTV-8 at a MOI of 0.01. At 24 h post-infection, cells were fixed and
analyzed by immunofluorescence as indicated in A. Scale bars correspond to 14 mm. (C) Confocal microscopy of C6/36 cells infected by BTV-1 and
A Novel BTV Non-Structural Protein
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terminal helix (residues 34 to 75) contains a conserved leucine
zipper domain, with leucine residues at positions 49, 56, 63 and 70
(Figure 1A).
We generated a polyclonal antiserum towards ORFX, in order
to assess whether BTV expressed this previously uncharacterized
protein. We detected ORFX in BSR cells infected with either
BTV-8 or BTV-1 by western blotting (Figure 1B). Controls
included BSR cells transfected with plasmids expressing ORFX
either in its native form, or with eGFP fused to its C terminus.
These data confirm that BTV expresses a protein encoded by an
alternative reading frame located in segment 9.
We subsequently investigated whether ORFX was a structural
or non-structural protein. We infected BFAE cells with BTV-1 and
analysed supernatants (containing viral particles) and total cellular
protein extracts. Unusually for mammalian cell lines, BFAE cells
show very little BTV induced cytopathic effect (CPE), thus
facilitating the efficient discrimination between all BTV proteins
present in the cellular fraction and the structural proteins present
in purified and concentrated viral particles released from infected
cells. By western blotting, we detected NS1 and ORFX in the
cellular fraction, while VP7 was abundantly present in the viral
fraction (concentrated by ultracentrifugation) and barely visible in
the cellular fraction (Figure 1C). We obtained the same results by
infecting C6/36 mosquito cells (data not shown). We detected VP6
in both the cellular and the viral fraction (Figure 1C). Interestingly,
unlike VP7, VP6 appeared to be relatively more abundant in cell
lysates compared to the viral pellets, suggesting that there is an
intracellular pool of this protein that is not incorporated in the
BTV virions.
The absence of ORFX in the viral pellet strongly suggested that
this is a non-structural protein expressed by BTV. In light of these
data, we designated this protein NS4. NS4 was also expressed in
vivo, as shown by immunohistochemistry of brain sections of mice
inoculated intracerebrally with BTV (Figure 1D).
NS4 localises predominantly in the nucleoli of transfected
and infected cells
By confocal microscopy of cells transiently transfected with pCI-
NS4, we observed that NS4 localized mainly in the nucleus
(Figure 2A) where it showed a strong co-localization with the
nucleolar marker B23 [40]. Importantly, cells infected with either
BTV-1 or BTV-8 also showed a strong nuclear co-localisation
between NS4 and B23 [40] (Figure 2B). We also observed NS4 to
localise in the nucleus of the C6/36 insect cells (Figure 2C).
NS4 does not have a canonical nuclear localization signal
(NLS) but possesses a stretch of basic amino acid residues, at the
amino terminus portion of the protein, that could drive nuclear
localization [41] (Figure 2D). We constructed an NS4 expres-
sion plasmid (pNS4-GFP) and a series of deletion mutants
(pNS47–77-eGFP, pNS413–77-eGFP and pNS419–77-eGFP) lack-
ing the 6, 12 and 18 amino terminal residues, respectively.
pNS4-GFP and pNS47–77-eGFP transfected cells showed a
strong nuclear localization ofN S 4 .O nt h eo t h e rh a n d ,N S 4
showed a predominantly cytoplasmic localization in cells
transfected with either pNS413–77-eGFP or pNS419–77-eGFP.
These data suggest that the amino terminal basic domain of
NS4 may play an important role in the nuclear localization of
this protein.
Interestingly, BFAE cells infected with BTV-1 revealed that
NS4 expression was evident as early as 2 hours post infection,
similar to that observed for other BTV structural and non-
structural proteins (Figure 3).
NS4 is dispensable for BTV replication
The data above clearly show that a previously uncharacterized
BTV protein, here referred to as NS4, is a non-structural protein
that localises to the nucleolus of infected cells. Next, we generated
by reverse genetics BTV NS4 deletion mutants in order to assess
the requirement of this protein for viral replication. We generated
a set of plasmids necessary for the rescue of BTV-1 and BTV-8
and engineered three mutations in the plasmids containing
segment 9 of BTV-1 and BTV-8 such that the NS4 initiation
codon was removed along with the introduction of two stop
codons in the NS4 coding sequence. All the mutations introduced
were designed in order to leave the VP6 amino acid sequence
unaltered (Figure 4A). As a negative control for BTV rescue, we
designed a VP6 deletion mutant with a premature stop codon
incorporated into the VP6 coding sequence (position 79). As
shown in Figure 4B, viable BTV1-DNS4 and BTV8-DNS4 were
rescued with similar efficiency to the respective wild-type (wt)
viruses, upon transfection of RNA transcribed in vitro from the
appropriate plasmids representing the genomic segments of wt or
mutated BTV-1 and BTV-8. As expected, BTV-1DVP6 and
BTV8-DVP6 could not be rescued.
We did not detect any variation in the migration pattern of
dsRNA genomic segments extracted from all the wt or the NS4
deletion mutant viruses (Figure 4C). The RNA profiles of both the
wt and DNS4 rescued viruses were identical to the corresponding
profile of the stock viruses from which the segments were originally
cloned. For each virus, segment 9 was completely sequenced in
order to confirm the presence of the introduced mutations.
We confirmed, by western blotting and confocal microscopy,
that the DNS4 mutants do not express NS4 but express levels of
VP7 and NS2 comparable to the parental wild type viruses. It was
also evident that in BSR cells BTV-8 expresses lower amounts of
NS4 relative to BTV-1 (Figure 4D and not shown). However,
BTV-1 replicates better than BTV-8 in these cells and differences
in the steady-state levels of VP7 between these two viruses were
also observed (Figure 4D). In cells infected by BTV1-DNS4 or
BTV8-DNS4, we found by electron microscopy all the ultrastruc-
tural features of BTV-infected cells (e.g. viral inclusion bodies,
NS1 tubules, viral particles) (Figure 4E).
We next assessed the replication kinetics of the rescued viruses
in a variety of mammalian and insect cell lines, including those
corresponding to the natural hosts (sheep and cattle) and vector
(midges). All subsequent experiments were performed using the
rescued versions of the wt viruses as they represent a more
homogenous population and are therefore more directly compa-
rable to the rescued DNS4 viruses. Cells were infected with a MOI
of 0.05 and supernatants were collected at various times post-
infection (Figure 5). No obvious difference was obtained in the
replication of wt and DNS4 viruses, regardless of the cell lines used
in the assay (Figure 5). Interestingly, the cell adapted BTV-1
viruses consistently grew more efficiently in vitro than the BTV-8
BTV-8 at a MOI of 0.05. At 48 h post-infection, cells were fixed and analyzed by immunofluorescence as for expression of NS4 as indicated in panel A.
Scale bars correspond to 11 mm. (D) Confocal microscopy of CPT-Tert cells transfected with pNS4-GFP or the truncated mutants indicated above each
panel. The red box corresponds to the first two amino terminal amino acid residues of NS4 that were maintained in all mutants. At 24 h post-
transfection, cells were fixed and analyzed by immunofluorescence. Scale bars correspond to 18 mm.
doi:10.1371/journal.ppat.1002477.g002
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PLoS Pathogens | www.plospathogens.org 6 December 2011 | Volume 7 | Issue 12 | e1002477Figure 3. NS4 expression profile. Confocal microscopy of BFAE cells infected with BTV-1 at a MOI of 1.5. Cells were fixed before infection (0 h)
and at 0 h30, 2 h, 4 h, 8 h, 16 h and 24 h post-infection and processed for immunofluorescence using antibodies against VP7, NS1, NS2, NS3 and NS4
with an Alexa Fluor 488 secondary antibody as described in the Materials and Methods. Scale bars correspond to 21.16 mm for 0 h to 4 h post-
infection panels, and 13.6 mm for 8 h to 24 h post-infection panels.
doi:10.1371/journal.ppat.1002477.g003
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(BFAE, CPT-Tert and KC).
BTV NS4 confers a replication advantage to BTV-8, but
not BTV-1, in mammalian cells treated with interferon
BTV, like most RNA viruses, is a strong inducer of interferon,
both in vivo in its natural hosts and in vitro [42–44]. Given that other
RNA viruses express proteins that counteract the innate immunity
of the host, we hypothesised that NS4 might aid BTV replication
in the presence of interferon (IFN). We treated cells with two type I
IFNs: IFN tau (IFNT) and universal IFN (UIFN). IFNT is secreted
by the ruminant conceptus and it is intimately linked to pregnancy
recognition signalling and possesses antiviral activity [45] while
UIFN is an alpha interferon hybrid constructed from recombinant
Human IFNs alpha A and alpha D, and is known to stimulate an
antiviral response in a wide variety of mammalian cells.
CPT-Tert cells were pre-treated with IFNT or UIFN for 20 h
prior to infection with BTV-1 or BTV-8 (or mock infection) with
MOIs ranging from 0.001 to 0.1. Both wt and the DNS4 mutants,
destroyed 80 to 100% (depending on the MOI used) of the
monolayer of infected cells in absence of IFN treatment (Figure 6).
On the other hand, pre-treatment with both types of IFN
significantly reduced BTV-induced CPE. Interestingly, in the
presence of IFN, BTV-8 wt consistently induced a more
pronounced CPE than BTV8-DNS4. Conversely, only minor
differences were observed in the CPE induced by both wt BTV-1
and BTV-1DNS4 in the presence of IFN (Figure 6).
Subsequently, we performed multi-step virus growth curves in
order to further assess the replication of BTV wt and DNS4 in the
presence or absence of IFN. CPT-Tert cells were treated with
interferon, as described above, and infected at a MOI of 0.01 with
wt and mutant viruses. At 24, 48 and 72 h post infection the cell
supernatants were collected and the virus titrated in susceptible
cells.
BTV-8DNS4 consistently reached lower titres (approximately
10 to 25 fold) than wt BTV-8 in cells treated with 1000 AVU/ml
of either IFNT or UIFN (Figure 7). Similar to what was observed
in the IFN protection assays, there was no discernable difference in
the replication growth of BTV-1 and BTV-1DNS4 after treatment
with either IFNT or UIFN. Similar patterns with both BTV-1 and
BTV-8 wt and the DNS4 mutant viruses where observed when the
input viruses were used at a MOI of 0.1 and 0.001 in CPT-Tert
(data not shown), or in BFAE cells treated with UIFN and infected
at a MOI of 0.1 (data not shown).
We next ruled out that the mutations inserted in segment 9 of
BTV-8DNS4 had a negative effect on VP6 expression (the other
protein expressed by segment 9). As shown in Figure 8A, BTV-8
wt and BTV-8DNS4 express similar amounts of VP6, reinforcing
the notion that the biological differences observed between these
two viruses were indeed due to the expression of NS4.
Therefore, the data presented so far suggested that either the
BTV-1 NS4 was somewhat defective or that the influence of this
protein on viral replication in the presence of IFN varies from
strain to strain. In order to discern between these two possibilities,
Figure 4. Generation of DNS4 Bluetongue viruses by reverse genetics. (A) BTV segment 9 open reading frames. VP6 amino acid residues are
written in black, NS4 amino acid residues are written in grey. The nucleotides at positions 183 (T), 252 (G) and 381 (T) were mutated to C, A and A,
respectively (bold). Note that whilst these mutations do not change any amino acid residues of VP6, they remove the initiation codon of NS4
(position182) and introduce two stop codons into the NS4 coding sequence at amino acid positions 24 and 67. (B) Transfected BSR cells with BTV
transcripts generated in vitro (0.5610
11 molecules per segment for BTV-1 and 1610
11 molecules per segment for BTV-8). Cell monolayers were
stained using crystal violet at 72 h post-transfection. As negative controls, DVP6 assays correspond to using a segment 9 containing a stop codon at
position 79 in the VP6 gene. (C) Agarose gel (1.5%) of purified BTV genomic dsRNA. BSR cells infected at a MOI of 0.01 were collected at 72 h post
infection and BTV dsRNA was purified as described in the Materials and Methods. 2 mg of dsRNA was loaded in each lane. (D) Western blotting of
cellular extracts (lysate) of BSR cells infected at a MOI of 0.01. Cells were analyzed 36 h post-infection and blots were incubated with antisera against
VP7, NS4 and c-tubulin as indicated. Note that the double NS4 band in the BTV-1 sample is not a feature observed consistently. (E) Electron
microscopy of BSR cells infected by BTV1-DNS4. Note cells display all the major features of BTV-infected cells including NS1 tubules (T), viral inclusion
bodies (VIB) and viral particles (arrows). Scale bar=1 mm.
doi:10.1371/journal.ppat.1002477.g004
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BTV-1 (BTV-8/1S9) or the DNS4 version (BTV-8/1S9DNS4).
Similarly, we derived BTV-1 reassortants containing the wild type
or mutated segment 9 of BTV-8 (BTV-1/8S9 and BTV-1/
8S9DNS4). In addition, we obtained a BTV-8 recombinant (BTV-
8/1NS4) with a single amino acid residue mutated in the NS4 (S to
Figure 5. In vitro growth properties of rescued WT and DNS4 viruses. Growth curves of BTV-8 (dark red, square), BTV8-DNS4 (red, triangle),
BTV-1 (blue, square) and BTV1-DNS4 (light blue, triangle) in cell lines derived from different species. BSR (hamster), BFAE (cattle), CPT-Tert (sheep), C6/
36 (mosquito) and KC (Culicoides) cells were infected at a MOI of 0.05 and supernatants collected at 8, 24, 48, 72 and 96 h after infection. Supernatants
were then titrated on BSR cells by limiting dilution analysis and the virus titers expressed as log10 (TCID50/ml). In parallel, each virus preparation was
also re-titrated by limiting dilution analysis to control that equal amounts of input virus was used in each experiment. Experiments were performed
independently twice, each time in duplicate, using two different virus stocks.
doi:10.1371/journal.ppat.1002477.g005
Figure 6. Cytopathic protection assay of CPT-Tert cells monolayer. CPT-Tert cells were treated or mock treated with 1000 AVU/ml of
interferon (Tau, IFNT or Universal, UIFN) for 20 h prior, and 2 h after, being infected by BTV-8 and BTV-1 (wt and DNS4) viruses at different MOIs (0.1,
0.01 and 0.001). Cell monolayers were stained at 72 h post-infection using crystal violet. Values indicated below each well correspond to the relative
quantification (in percent) of the disrupted monolayer using Image-Pro Plus (MediaCybernetics, Inc.).
doi:10.1371/journal.ppat.1002477.g006
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homologous BTV-1 protein (Figure 8B). Both cytopathic
protection assays and multistep growth assays clearly showed
that BTV-8/1S9 replicated more efficiently than BTV-8/
1S9DNS4 in the presence of IFN (Figure 8C, D). Similar results
were obtained with BTV-8/1NS4, which replicated more
efficiently than BTV-8DNS4 in cells pre-treated with IFN, while
no major differences were observed between BTV-1/8S9 and
BTV-1/8S9DNS4. Collectively, these data strongly indicate that
the NS4 of BTV-1 is not defective and can function within the
context of BTV-8.
DNS4 BTV mutants are pathogenic in mice models of
disease
Next, we assessed the virulence of DNS4 BTV mutants in two
murine models of bluetongue infection [46,47]. 129sv IFNAR
(2/2)
mice, which are deficient in the type I IFN receptor, are
susceptible to infection and disease induced by BTV inoculated
by various routes [46,48]. Newborn NIH-Swiss mice inoculated
intracerebrally are also susceptible to BTV infection [47]. These
models have been previously used to assess BTV virulence [47,49].
In this study, we infected 129sv IFNAR
(2/2) mice with either
BTV-1, BTV-8 or the corresponding DNS4 mutants. No major
differences were observed in the virulence of wild type and DNS4
viruses; all viruses employed in this study killed 100% of the
inoculated mice by day 8 post-infection (Figure 9). We also
inoculated 3-day old NIH-Swiss mice intracerebrally with the
same viruses as above. Once again, both wild type and DNS4
viruses were able to kill 100% of the inoculated mice with no
major differences in the virulence observed (Figure 9).
Discussion
In this study we have shown that BTV expresses a previously
uncharacterised non- structural protein that favours viral replica-
tion in cells in an antiviral state. By constructing deletion mutants
by reverse genetics, we showed that NS4 is dispensable for viral
replication in vitro, both in mammalian and insect cells, and in vivo
in murine experimental models. However, the coding sequence in
the NS4 reading frame of segment 9 is highly conserved in BTV
and in related Orbiviruses [29,50], suggesting that it must be
essential for the maintenance of BTV in nature. Indeed, we have
found that NS4 confers a replication advantage to BTV-8 in cells
pre-treated with type I IFN.
We found NS4 to have strong nucleolar localization, although it
may shuttle between the nucleolus and cytoplasm and possibly
carry out its biological functions in the latter. The nucleolus is a
dynamic sub-nuclear structure that plays crucial roles in ribosome
subunit biogenesis, the response to cellular stress and cell growth
[51,52]. Several examples of viral proteins targeting the nucleolus
have been discovered in recent years [53]. The retroviral Rev and
Rev-like proteins for example, shuttle between the nucleolus and
cytoplasm, and function as post-transcriptional regulators of viral
gene expression [54–57]. One of the main functions of these
proteins is to facilitate the export of unspliced viral mRNA
(transcribed from the proviral DNA copy of the retroviral genome
Figure 7. In vitro growth properties of rescued WT and DNS4 viruses during interferon treatment. CPT-Tert cells were treated (solid line)
or mock treated (dashed line) with 1000 AVU/ml of interferon (Tau, IFNT or Universal, UIFN) for 20 h prior and 2 h after being infected by BTV-8 (dark
red, square), BTV8-DNS4 (red, triangle), BTV-1 (blue, square) and BTV1-DNS4 (light blue, triangle) viruses. Cells were infected at a MOI of 0.01.
Supernatants were collected at 24, 48 and 72 h after infection, and then titrated on BSR cells by limiting dilution analysis and virus titers expressed as
log10 (TCID50/ml). In parallel, each virus preparation was also re-titrated by limiting dilution analysis to control that equal amounts of input virus was
used in each experiment. This experiment was performed three times, each time in duplicate.
doi:10.1371/journal.ppat.1002477.g007
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RNA structure in the viral RNA and the karyopherin export factor
Crm1 (chromosome region maintenance 1) [58]. Other RNA
viruses (including those that replicate exclusively in the cytoplasm)
have also been found to possess proteins that target the nucleoli.
Examples include, among others, avian infectious bronchitis virus
[59], porcine reproductive and respiratory syndrome virus [60],
Newcastle disease virus [61], Semliki forest virus [62], dengue
virus [63], West Nile virus [64], influenza virus [65], avian
reovirus [66] and encephalomyocarditis virus [67,68] The reasons
for the nucleolar targeting of many of these proteins have not
always been entirely clear.
Figure 8. The NS4 of BTV-1 displays similar biological properties to the homologous BTV-8 protein. (A) Western blotting of cellular
extracts (lysate) of CPT-Tert cells infected with BTV-8 wt or BTV-8DNS4 at a MOI of 0.01. Cells were analyzed 24 h post-infection and blots were
incubated with antisera against NS1, VP7, VP6, NS4 and c-tubulin as indicated. (B) Schematic diagram of the BTV-8/BTV-1 reassortants and mutants
used in this study. Note that BTV1 and BTV8 segments/proteins are coloured in blue and red, respectively. * indicates a point mutation, while #
indicates the introduction of a stop codon in the NS4 ORF. (C) CPT-Tert cells were treated with 1000 AVU/ml of Universal IFN for 20 h prior, and 2 h
after, being infected by the recombinant viruses indicated in the panel using a MOI of 0.01. Cell monolayers were stained 72 h post-infection using
crystal violet. Values indicated below each well correspond to the relative quantification of the disrupted monolayer using Image-Pro Plus
(MediaCybernetics, Inc.). (D) CPT-Tert cells were treated (solid line) or mock treated (dashed line) with 100 AVU/ml of Universal interferon (UIFN) for
20 h prior and 2 h after being infected by the viruses indicated in the panel. Cells were infected at a MOI of 0.01. Supernatants were collected at 24,
48 and 72 h after infection, and then titrated on BSR cells by limiting dilution analysis and virus titers expressed as log10 (TCID50/ml). In parallel, each
virus preparation was also re-titrated by limiting dilution analysis to control that equal amounts of input virus was used in each experiment. This
experiment was performed two times, each time in duplicate.
doi:10.1371/journal.ppat.1002477.g008
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major component of the inner capsid shell. Although the sA
protein localises mainly in viral factories in the cytoplasm of
infected cells, it also localizes in the nucleoli [66]. sA has a strong
affinity for dsRNA and it may provide protection against the IFN-
induced and dsRNA dependent PKR response. Interestingly, sA
mutants that do not bind dsRNA are also unable to reach the
nucleoli, suggesting that dsRNA binding and nucleolar targeting
may be strictly linked [69].
BTV NS4 may also bind nucleic acids but, unlike the reovirus
sA, we show strong evidence that NS4 is not a structural protein.
Indeed, by western blotting we did not detect NS4 in viral particles
but only in lysates of BTV infected cells. In addition, by confocal
microscopy we did not detect NS4 in viral inclusion bodies but
predominantly in the nucleoli of viral infected cells. We cannot
exclude completely that small amounts of NS4, below the limits of
detection of our western blotting analysis, are present in viral
particles.
The predicted structural features of NS4 resemble those of a
transcription factor of the bZip family with a basic domain
followed by a leucine zipper motif [70]. Thus, NS4 may function
as a nucleic acid binding protein and either repress or enhance
transcription of genes linked directly or indirectly to the IFN
response of the cell. However, a BTV-8 recombinant virus (BTV-
8DLZNS4) expressing an NS4 with all the 4 leucine residues
forming the putative leucine zipper mutated (into either glutamine
or serine) replicated as efficiently as BTV-8 wt in cells pre-treated
with IFN (data not shown). Thus, more studies will be necessary to
explore this possibility.
The organization of VP6/NS4 ORFs in segment 9 of BTV
mirrors that of NSP5/NSP6 in the rotavirus segment 11 [71]. The
rotavirus NSP6 is not essential for virus replication but unlike the
BTV NS4, does not localize in the nucleus of infected cells [72].
To date, limited information is available on the interplay
between BTV and the host innate immune system. BTV has been
recognized as a potent inducer of type I IFN in sheep [42], cattle
[43] and mice [73]. However, limited data have been available on
how BTV induces the IFN response of the cell and, more
importantly, what counteracting measures the virus utilises to
overcome this response. Our data suggest that BTV may use NS4
to defend itself from the innate immune response of the host given
that replication of BTV8-DNS4 in cells treated with IFN is 10 to
25 fold less efficient compared to wild type BTV-8. In addition, the
cytopathic effect in cells treated with IFN is more pronounced
when cells are infected by wild type BTV-8 compared to cells
infected by BTV8-DNS4.
Viruses have evolved a variety of strategies to evade the host
innate immunity [74]. Other dsRNA viruses such as rotaviruses,
use different mechanisms (which vary between strains and the type
of infected cells) to modulate the type I IFN response. For
example, rotaviruses use NSP1 protein to promote the protea-
some-dependent degradation of IRF proteins [75–77] and mediate
repression of NF-kB, resulting in a reduction of IFN induction
[78]. Rotaviruses also induce shut off of cellular protein synthesis
resulting from the detection of dsRNA by PKR which, in turn is
responsible for phosphorylation and consequent inhibition of the
eukaryotic translation initiation factor eIF2a [79]. The blocking of
host cell protein synthesis is another likely strategy used by some
RNA viruses to counteract the IFN response [67,68]. BTV also
blocks host cell protein synthesis early after infection, although the
mechanisms underlying this phenomenon are not clear [27].
Interestingly, we found that BTV1-DNS4 replicated as
efficiently as wild type BTV-1, even in cells treated with IFN.
However, the NS4 of BTV-1 appears to possess the same
biological properties of the NS4 of BTV-8. Indeed, a BTV-8
reassortant containing the entire segment 9 of BTV-1 (BTV-8/
1S9) or a recombinant BTV-8 expressing an NS4 100% identical
to the homologous BTV-1 protein (BTV-8/1NS4), maintained the
phenotype of wt BTV-8. Thus, it is possible that the role played by
NS4 in counteracting the IFN response of the host could vary
between different virus strains. It is important to stress that the
strain of BTV-8 that we used in this study has been passaged only
a few times in culture (once in KC cells and three times in BHK21
cells) after isolation from blood of an infected animal. On the other
hand, BTV-1 was derived from the ‘‘reference’’ South African
strain passaged twice in embryonated eggs and 9 times in BHK21.
Figure 9. Experimental infection of Swiss new born and
IFNAR
(2/2) adult mice with wt and DNS4 viruses. Survival plots
of either 3-days old mice inoculated intracerebrally or adult sv129
IFNAR
(2/2) inoculated intraperitoneally with the following viruses: BTV-
8 (dark red, square), BTV8-DNS4 (red, triangle), BTV-1 (blue, square) and
BTV1-DNS4 (light blue, triangle) viruses. Mock-infected mice are shown
in gray, circle. Mice were killed at two weeks post-inoculation, or earlier,
if showing advanced clinical signs of systemic disease.
doi:10.1371/journal.ppat.1002477.g009
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especially at the early time points post infection. Thus, faster
replication may help BTV1-DNS4 to escape the IFN response of
the cell more efficiently, as already suggested for some strains of
influenza, and this may render NS4 less critical in these in vitro
assays [80].
More in vivo experiments will be needed in order to determine
the role of NS4 in the interplay with the natural host of BTV
infection. We observed no differences between wild type BTV-8
and BTV8-DNS4 in experimental mouse models, although it
remains possible that differences could be identified in sheep. It is
possible that NS4 is required for viral replication in insects,
although we have established in this study that no differences are
observed on the replication of the DNS4 mutants in insect cells in
vitro.
In conclusion, in the present study we have identified a
previously uncharacterized non-structural protein of BTV. The
identification of this highly conserved protein opens the way to
understand finer details of virus-host interaction and pathogenesis.
In addition, the distinct nucleolar localization, in a virus that
replicates exclusively in the cytoplasm will offer new avenues to
understand the various roles played by these organelles in the
biology of the cell.
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